SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

Agreed. Investor NDAs covered (a) the existence and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
thermoo Member Profile
 
Followed By 4
Posts 27
Boards Moderated 0
Alias Born 10/27/16
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/7/2017 4:33:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 12/5/2017 5:25:14 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/21/2017 6:05:58 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/20/2017 5:33:26 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 11/14/2017 5:20:39 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/24/2017 3:19:13 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/16/2017 5:28:13 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/22/2017 5:11:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/22/2017 4:18:34 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/22/2017 8:58:57 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 9/11/2017 2:46:27 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 9/11/2017 2:41:35 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/21/2017 4:40:00 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) "Edgar (US Regulatory)" - 8/15/2017 4:12:02 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/8/2017 5:28:51 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 5:24:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 8/7/2017 5:19:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/7/2017 1:14:16 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/26/2017 3:21:58 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/21/2017 5:17:26 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/29/2017 4:27:47 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/27/2017 5:02:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2017 5:20:48 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/13/2017 5:08:50 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 6/1/2017 10:28:04 AM
thermoo   Thursday, 12/07/17 06:15:23 PM
Re: VuBru post# 148261
Post # of 149694 
Agreed. Investor NDAs covered (a) the existence and terms of the transaction prior to those being released in an 8k (this would include voting arrangements, etc), and (b) a separate NDA covering certain fundamental information about the trial / company.

All investors would have to sign "a". This NDA would prohibit trading until the 8k is released. NDA "b", while optional, would give long term investors comfort that the technology is compelling. The can't sell until the fundamental data is publicly available but why would they? If there is a significant therapeutic benefit, the stock is not going to stop at $0.50


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist